The rest of this page explains how that decision gets made, what the delivery forms have in common, what monitoring looks like once therapy is under way, and why a borderline number on its own rarely changes anything.
Prescribed testosterone therapy supplies testosterone from outside the body so that circulating levels sit closer to a range the prescriber is aiming for, in people whose own production has been confirmed low. It replaces a missing signal rather than repairing the gland or the pathway that stopped working, which is why it is an ongoing form of care rather than a one-off fix.
The normal loop runs from the hypothalamus, which releases GnRH, to the pituitary, which releases LH and FSH, to the testes, where LH drives testosterone production and FSH supports sperm production. Testosterone then acts at androgen receptors in muscle, bone, skin, brain and sexual tissue. Part of it converts to dihydrotestosterone, and part converts to estradiol through the aromatase enzyme, which is why estradiol is not a female-only marker and why it matters for bone density, mood and libido in men too.
That loop runs on negative feedback. When testosterone arrives from outside the body, the brain reads the higher level and dials its own signal down, so natural production and sperm output fall during therapy 1. Clinical guidelines describe the goal of therapy in men with hypogonadism as raising testosterone toward a target range and improving the symptoms tied to deficiency, not as chasing a high number 2.
Research suggests that, in men with confirmed hypogonadism, therapy is associated with improvement in sexual function and in some measures of body composition 3. Benefit is not uniform across every symptom or every person, and a licensed provider evaluates whether the likely gain is worth the trade-offs in any individual case.
It is for people with hypogonadism that has been confirmed both ways, meaning consistently low morning testosterone measured on more than one occasion alongside symptoms or signs that fit the picture. Urology guidance defines testosterone deficiency using exactly that pairing, low measured levels plus clinical features, rather than either one alone 4. The 2025 European guideline update on male hypogonadism describes the same requirement, that the biochemistry and the clinical picture both have to line up before therapy is considered 5.
The symptoms that most often prompt testing include reduced libido, erectile difficulty, persistent fatigue that sleep does not fix, low mood or flat motivation, loss of muscle mass with gain in fat mass, reduced body hair, and in some cases hot flushes or reduced bone density found on a scan. None of these is specific on its own. Poor sleep, low iron, thyroid problems, depression, heavy alcohol use and chronic illness can all produce the same list, which is part of why a prescriber works through alternatives before landing on a hormone explanation.
It is generally not for someone who is trying to conceive in the near term, since suppression of sperm production is an expected effect of exogenous testosterone 1. Guidelines also describe situations where therapy is not offered or is deferred, including active prostate or breast cancer, poorly controlled heart failure, severe sleep apnoea that has not yet been addressed, and a red cell concentration that is already elevated at baseline 2. Your prescriber decides whether any of those apply to you after a full evaluation.
Confirmation means at least two separate morning blood draws showing low testosterone, interpreted alongside symptoms and a handful of supporting markers. Guidelines are explicit that a single low value is not enough, because testosterone moves meaningfully from day to day and even hour to hour 2.
Timing matters more than most people expect. Testosterone follows a daily rhythm that peaks in the morning in younger men and flattens with age, so samples are usually drawn early in the day. Eating lowers measured testosterone, so a fasting morning draw is the cleaner comparison. Acute illness, a recent hospital stay, heavy training in the previous day or two, and severe sleep restriction can all pull a reading down temporarily, which is why testing during a rough week produces a number that may not represent your baseline.
When the total result sits near the bottom of the standard range, prescribers often look further, because total testosterone includes the portion bound tightly to sex hormone binding globulin and not available to tissue. Obesity, insulin resistance, thyroid status, liver conditions and ageing all shift that binding protein, so free testosterone or a calculated free value can change the interpretation. Guidelines recommend measuring LH and FSH to separate a testicular cause from a pituitary or hypothalamic one, and adding prolactin and iron studies when the pattern points upstream 2.
That sequence is what turns a number into a decision. The observation is a low reading. The possible meaning is primary testicular underproduction, a signalling problem higher up, or a temporary dip caused by something fixable. The next step is a repeat draw under clean conditions and a conversation with a clinician about which of those fits.
Several delivery routes exist, including injectable, topical, transdermal, implanted and oral or nasal forms, and guidelines describe the choice as depending on how steady levels need to be, patient preference, cost and the specific risks of each route 2 1. The active hormone is the same across routes. What changes is how quickly it enters circulation, how steady the resulting levels are, and what practical issues come with it.
| Delivery form | How it generally works | What a prescriber may consider |
|---|---|---|
| Injectable | Hormone is delivered into muscle or under the skin and released into circulation over a period set by the formulation | Level patterns between administrations, red cell response, comfort with self-administration |
| Topical gel or cream | Applied to the skin and absorbed through it | Risk of transfer to a partner or child through skin contact, absorption variability, skin irritation |
| Transdermal patch | Worn on the skin and absorbed steadily through it | Local skin reactions, adhesion, visibility |
| Implanted pellet | Placed under the skin during a minor in-office procedure and released slowly | Requires a procedure, less flexibility to adjust once placed, site healing |
| Oral, buccal or nasal | Absorbed through the gut lining, the gum or the nasal lining | Administration frequency, local tolerance, suitability varies by individual |
No delivery form is universally better. Each one trades something, usually convenience against how smooth the resulting levels are, and a licensed provider evaluates which trade-off suits a given person. Doses, schedules and administration technique are decided and taught by the prescribing clinician, never chosen from an article.
The choice usually comes down to level stability, household safety, monitoring practicality and what someone will realistically stick with. Formulations differ in how quickly levels rise and fall, and that pattern influences both how steady symptoms feel and how markers such as red cell concentration respond over time 1.
FitScript works with licensed providers across all 50 states; specific treatment availability can vary by state and is confirmed during your provider evaluation.
The decision to start weighs confirmed biochemistry, matching symptoms, fertility plans, baseline safety markers and anything reversible that could be driving the low result. Guidelines frame it as a shared decision after the deficiency is established, not an automatic consequence of a low number 2.
Reversible contributors come first. Significant weight gain, untreated sleep apnoea, chronic sleep debt, very high training loads with low energy intake, heavy alcohol use, uncontrolled blood sugar and certain long-term prescriptions can all suppress testosterone. Addressing those sometimes moves levels without hormone therapy at all, and it almost always improves how someone responds if therapy does go ahead.
Fertility planning comes next, because it is one of the few decisions that is awkward to reverse quickly. Someone who wants children in the next few years has a genuinely different conversation from someone who does not, and that conversation belongs at the start rather than after therapy has been running.
Baseline safety markers then set the floor. A prescriber typically wants a starting red cell concentration, a prostate assessment in men for whom screening is appropriate, a lipid picture, blood pressure and a symptom inventory to compare against later. Cardiovascular history is part of this review. Research suggests that testosterone therapy in men with hypogonadism is not consistently linked to an increase in cardiovascular events, and cardiovascular risk is still assessed before starting and followed afterwards 6.
Because the expected benefit is small and the trade-offs are real. Guidelines recommend against starting in men who do not have both consistently low measured testosterone and symptoms that fit, which rules out treating a number in isolation 2 4.
There are three practical reasons behind that position. First, standard lab reference ranges are built from population distributions, so a result in the lower part of the range is common rather than abnormal, and a person who feels well at that level has no symptom to improve. Second, testosterone varies enough between draws that a single low-normal value may simply be a low-normal day. Third, starting therapy suppresses the body's own production, so someone with a mild, symptom-free dip may trade a self-sustaining system for a dependent one without gaining much.
A borderline result with real symptoms is still worth investigating, since the answer may lie in free testosterone, binding globulin, sleep, metabolic health or thyroid status rather than in a prescription. That investigation is a conversation with a clinician, not a self-assessment.
Monitoring follows the testosterone level itself plus a short list of safety markers, repeated at intervals the prescriber sets. The point is to confirm that levels are landing where intended and to catch the predictable side effects early, while they are easy to address.
Hematocrit is the marker most consistently followed. Guidelines recommend checking it before starting and during therapy, because erythrocytosis, a rise in the concentration of red cells, is associated with testosterone therapy 2. PSA is followed in men for whom prostate screening is appropriate, with a baseline assessment before starting and periodic checks afterwards 4. Estradiol is sometimes measured, because a portion of testosterone converts to it, and prescribers may look at it when symptoms such as breast tenderness or fluid retention show up.
| What is followed | Why it is followed |
|---|---|
| Testosterone level | Confirms levels are landing in the range the prescriber is targeting, interpreted against when the sample was drawn |
| Hematocrit and full blood count | Red cell concentration can rise during therapy and is the most common reason care is paused or changed |
| PSA and prostate assessment | Baseline and follow-up in men for whom screening is appropriate |
| Estradiol | Part of testosterone converts to estradiol, relevant when related symptoms appear |
| Lipids and blood pressure | Part of the broader cardiovascular picture reviewed alongside therapy |
| Symptom review | The outcome that actually matters, tracked against the baseline recorded before starting |
A result that sits outside the standard range is suboptimal, not a verdict. It is a prompt to look at timing, technique, dose decisions and context with the clinician who prescribed the therapy, and a marked change is worth discussing with a clinician promptly.
The known risks are mostly predictable, mostly detectable on routine bloodwork, and mostly manageable when someone is actually being monitored. The most consistent one is a rise in red cell concentration, which is why hematocrit is followed throughout and why guidance builds monitoring around it 2.
Cardiovascular considerations sit alongside these. Research suggests that testosterone therapy in men with hypogonadism is not consistently linked to an increase in cardiovascular events, and prescribers still review cardiovascular risk as part of ongoing care 6. None of this means a given person will experience any of it. It means these are the things worth watching, and watching them requires bloodwork and a prescriber.
It suppresses both, by design of the feedback loop rather than as a surprise. Testosterone arriving from outside the body reduces the pituitary's release of LH and FSH, which lowers the very high local testosterone concentration inside the testes that sperm production depends on, and sperm output falls as a result 1.
This is the same mechanism behind hypogonadism seen after supraphysiologic androgen use, where the suppressed axis can take a prolonged and unpredictable period to recover, and in some cases does not return fully to baseline 7. The relevant point for anyone considering therapy is that recovery timelines are not something a clinician can promise in advance, so fertility plans should be on the table before the first prescription rather than after.
There are approaches a prescriber may consider for someone who wants to preserve fertility, and there are reasons a prescriber may recommend waiting or pursuing a different route entirely. Those options are chosen by a licensed provider after an evaluation, and they depend on the cause of the low testosterone, age, baseline semen analysis and how soon conception is planned. Testicular size can also decrease during therapy, which some people find notable and which relates to the same reduction in signalling.
If fertility matters to you now or might in the future, say so explicitly at the first appointment. It changes the shape of the plan more than almost any other piece of history.
Because it removes every safeguard that makes prescribed therapy reasonably predictable, while keeping all of the physiology. The suppression of natural production happens either way. What disappears is the confirmed diagnosis, the baseline markers, the monitoring that catches a rising red cell count, and the clinician who can change course.
The pattern is well described. Androgen use outside medical supervision, particularly at supraphysiologic levels, suppresses the hypothalamic-pituitary-testicular axis and can leave someone hypogonadal and subfertile well after use stops, with recovery that is slow and not guaranteed 7. People who start this way often arrive at a clinic later with symptoms that are now harder to sort out, because the original baseline no longer exists to compare against.
There are practical problems too. Product sourced outside a pharmacy has unverified identity, concentration and sterility. Without monitoring, a red cell concentration can drift upward unnoticed, estradiol-related symptoms go unexplained, and prostate markers are never baselined. And without a diagnosis, there is no way to know whether low testosterone was ever the issue, which means the symptom that prompted everything may go unaddressed while a new problem is created.
If you have already used non-prescribed testosterone, that history is worth telling a clinician plainly. It changes how results are interpreted and what the sensible next step is, and clinicians are far more interested in the information than in the judgement.
Testosterone rarely answers the question on its own, so it is usually run with markers that explain where a low result comes from and markers that keep therapy safe. Guidelines recommend LH and FSH to distinguish a testicular cause from a pituitary or hypothalamic one, with prolactin and iron studies added when the upstream pattern is suspected 2.
FitScript's membership includes 150+ biomarkers tested per year, which is the kind of breadth that lets a low testosterone result be read in context rather than in isolation.
Ongoing care is a loop of symptom review, blood testing and adjustment decisions made by the prescriber, repeated at intervals that are set individually. Guidelines describe monitoring as continuing for as long as therapy continues rather than stopping once levels look acceptable once 2.
Early on, the focus is confirming that levels are landing where intended and that nothing is drifting. Sample timing relative to administration matters here, and the prescriber specifies when to draw so results are comparable between visits. Later, the focus shifts toward whether the symptoms that justified therapy have actually improved, because that is the outcome being purchased, and toward the safety markers that need continued attention.
Dose and formulation decisions belong entirely to the prescriber. So does the decision to pause, stop or restart. Stopping is sometimes the right call, and it is a managed process rather than something to do abruptly on your own, since the body's own production does not resume instantly.
One honest expectation to set is that symptom change is uneven. Some things shift relatively early, others take longer, and some symptoms turn out to have had a different cause all along. Tracking symptoms in writing from before you start gives you something more reliable than memory to compare against at the next review.
It is worth talking to a clinician whenever persistent symptoms that fit low testosterone show up, and before acting on any result you have in hand. Testing is the beginning of that conversation rather than a substitute for it.
Book a conversation if you have ongoing low libido, erectile difficulty, unexplained fatigue, loss of muscle with gain in fat, low mood or poor recovery that has lasted beyond a few weeks. Book one if a result has come back below the standard range, even if you feel reasonably well, because a repeat draw under clean conditions is the next step. Book one before starting anything if conception is in your plans.
If you are already on therapy, contact your prescriber promptly if you notice chest pain, breathlessness, swelling in one leg, severe headaches or vision changes, or if a routine result shows a marked rise in red cell concentration. Mood changes, breast tenderness, worsening snoring or daytime sleepiness are also worth raising rather than waiting for the next scheduled review. Never stop or change prescribed therapy on your own, and never ignore a result that falls outside the standard range.
This article is educational and is not medical advice. Discuss your results and any treatment decision with a clinician or licensed provider who can evaluate your full history.
For more on how prescribed hormone care is structured, FitScript's page on testosterone care for men covers what a provider evaluation involves, and the testosterone therapy monitoring panel page lists the markers typically followed once therapy is under way.
No form is universally better. They deliver the same hormone and differ mainly in how steady the resulting levels are, how they are administered, and practical issues such as skin transfer to other household members with topical forms. A licensed provider weighs those factors against your preferences and history and decides which one fits.
Generally not. Testosterone varies from day to day and across the day, so a low result is usually repeated on a separate morning under fasting conditions before it is taken as real. Supporting markers such as LH, FSH and sex hormone binding globulin are often added to work out where the low level is coming from.
Yes, suppression of sperm production is an expected effect, because testosterone from outside the body reduces the brain signals that drive the testes. How fully and how quickly that recovers after stopping is unpredictable. If you want children now or later, raise it at the first appointment so your prescriber can factor it into the plan.
Typically the testosterone level itself, a full blood count including hematocrit, prostate markers where screening is appropriate, estradiol when related symptoms appear, plus lipids, blood pressure and a structured symptom review. Timing of the blood draw relative to administration matters, so your prescriber will tell you when to test. The intervals are set individually.
A rise in red cell concentration is the most common reason therapy gets adjusted or paused, which is why hematocrit is measured before starting and repeated afterwards. A reading above the standard range is suboptimal rather than a verdict, and it is worth discussing with your prescriber promptly so they can decide what to change.
That situation deserves investigation rather than an automatic prescription. Free testosterone, sex hormone binding globulin, thyroid markers, ferritin, sleep quality and metabolic markers can all explain symptoms that look hormonal. Bring the full picture to a clinician, who can decide what else to measure and whether therapy is appropriate at all.
Your body still reduces its own production, but without a confirmed diagnosis, baseline markers or monitoring to catch problems early. Product sourced outside a pharmacy also has unverified identity, strength and sterility. If you have already used testosterone this way, tell a clinician plainly, because it changes how your results should be read.
For most people with confirmed hypogonadism it is ongoing care rather than a short course, because the underlying production problem remains. It can be stopped, but that is a managed decision made with your prescriber, since natural production does not resume immediately. Never stop or change prescribed therapy on your own.